What is the 13F Pro Quality Score for HALO?

13F Pro ranks HALOZYME THERAPEUTICS, INC. (HALO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HALO's current score at https://13fpro.ai/company/HALO (free sign-up required for the full ranking).

Where does 13F Pro source HALO data?

All HALOZYME THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. HALOZYME THERAPEUTICS, INC. files with the SEC under CIK 1159036. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HALO in?

HALOZYME THERAPEUTICS, INC. (HALO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives HALO's revenue?

Per HALOZYME THERAPEUTICS, INC.'s latest 10-Q filed with the SEC on 2026-08-06, the biggest revenue drivers are: Royalties ($307.7M, +50% YoY); DARZALEX ($152.2M, +27% YoY); VYVGART Hytrulo ($72.6M, +143% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/HALO.

What are HALO's largest expenses?

HALOZYME THERAPEUTICS, INC.'s latest 10-Q reports these as the largest expense items: Cost of sales ($79.2M, +71% YoY); Selling, general and administrative ($57.0M, +37% YoY); Amortization of intangibles ($29.5M, +66% YoY). Sourced directly from SEC EDGAR filing text for Q2 2026 (quarter ended June 30, 2026).

How often is HALO research updated on 13F Pro?

HALO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

HALOZYME THERAPEUTICS, INC.(HALO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1159036 HALO stock profile & AI dashboard →

13F Pro Quality Score

77.2/100

Rank #72 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

91.0/100

Profitability

79.0/100

Balance Sheet

95.0/100

Earnings Quality

83.6/100

Free Cash Flow

94.4/100

Institutional Flow

30.9/100

Revenue Scale

59.9/100

Dilution Risk

29.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why HALO Scores 77/100

exact factor attribution · 2026-09-11

HALO's composite is driven by revenue growth and free cash flow, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.2 pts

91th pct

Free cash flow

+6.7 pts

94th pct

Capital efficiency

+4.5 pts

95th pct

Profitability

+4.3 pts

79th pct

Earnings quality

+3.4 pts

84th pct

Scale

+1.5 pts

60th pct

Earnings growth

+0.7 pts

64th pct

Institutional flow

-1.0 pts

31th pct

Shareholder dilution

-1.0 pts

29th pct

Latest change (2026-08-08): 81 → 76 · ↓ Profit margin 95→83; ↓ Earnings growth 84→49

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

HALO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for HALOZYME THERAPEUTICS, INC. (HALO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HALO at 77.2/100 on a 32-signal composite quality model, placing it at rank #72 of 2,961 stocks — the top 5% of the AI-ranked universe. HALO scores in the top quartile across balance sheet strength (95.0), free cash flow (94.4), revenue growth (91.0). Areas of concern include institutional flow (30.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 29.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), HALOZYME THERAPEUTICS, INC. reports quarterly revenue of $481.0M, net income of $229.9M, free cash flow of $236.7M. Top institutional holders of HALO by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. HALO trades on the Nasdaq exchange and files with the SEC under CIK 1159036. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HALO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HALOZYME THERAPEUTICS, INC. directly from SEC EDGAR. HALOZYME THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 62 and 84 since 2021, currently 77.2 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about HALOZYME THERAPEUTICS, INC.

Quirks, history, and lore behind HALO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · mid-cap · listed on Nasdaq · headquartered in San Diego, California.
2
The Numbers
Annual revenue in the hundreds of millions, driven almost entirely by royalties and licensing deals rather than selling drugs directly to patients.
3
The History
Founded in the early 2000s, the company spent years developing a single platform technology before pivoting to a royalty-based business model that made it far more profitable than a typical biotech.
4
The Secret
Its crown jewel is an enzyme technology that makes drugs absorb faster and more efficiently — essentially a biological shortcut that other drugmakers pay handsomely to borrow.
5
The Lore
Its ENHANZE drug-delivery platform is embedded in blockbuster treatments sold by Roche, Pfizer, Janssen, and others — meaning it quietly profits every time those giant drugs are administered.
6
The Giveaway
The company's name literally nods to hyaluronidase — the enzyme at the heart of its ENHANZE technology — and its ticker is the friendliest four letters in biotech: HALO.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving HALO's Business? Latest 10-Q Breakdown

AI-extracted from HALOZYME THERAPEUTICS, INC.'s 10-Q filed 2026-08-06 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenue rose to $481.0M from $325.7M as royalties grew 50% to $307.7M on DARZALEX SC and VYVGART Hytrulo uptake, with net income of $229.9M.

Biggest Revenue Drivers

Royalties$307.7M+50% YoY

Continued sales uptake of ENHANZE partner products launched since 2020, partially diluted by price erosion on Herceptin and MabThera

Product sales, net$129.6M+59% YoY

Increased bulk rHuPH20 sales driven by partner demand, plus XYOSTED contributions from continued market growth

Biggest Revenue Drivers

Total revenue: $481.0M

Royalties$307.7M+50% YoY

Continued sales uptake of ENHANZE partner products launched since 2020, partially diluted by price erosion on Herceptin and MabThera

Within Royalties

DARZALEX$152.2M+27% YoY

VYVGART Hytrulo$72.6M+143% YoY

Product sales, net$129.6M+59% YoY

Increased bulk rHuPH20 sales driven by partner demand, plus XYOSTED contributions from continued market growth

Revenues under collaborative agreements$43.7M+13% YoY

Primarily due to the timing of milestones achieved; included $35.5M of upfront license and target nomination fees

Largest Expense Items

Cost of sales$79.2M+71% YoY

Primarily due to an increase in bulk rHuPH20 sales

Selling, general and administrative$57.0M+37% YoY

Consulting and professional fees including patent infringement litigation costs, the Elektrofi and Surf Bio acquisitions, and higher compensation expense

Amortization of intangibles$29.5M+66% YoY

Due to the acquisition of Elektrofi in November 2025

Research and development$27.7M+58% YoY

Primarily due to the acquisition of Elektrofi and Surf Bio in the fourth quarter of 2025

Margins: The filing gives no explicit gross or operating margin discussion; it attributes the 71% cost of sales increase to higher bulk rHuPH20 sales, against total operating expenses of $193.3M and operating income of $287.7M.

Watch Items from the Filing

A partner may return a Hypercon target by February 2027; if so, the $450.6M customer relationship intangible and goodwill could face a material interim impairment charge.
Collaboration revenue is lumpy: sales-based milestones fell to zero from $10.0M and event-based milestones to $5.7M from $24.5M year over year.
Total convertible note principal of $2.18B, with $209.6M of 2027 Notes now classified as current portion of long-term debt against $231.0M of cash and marketable securities.
New May 2026 program to repurchase up to $1.0B of stock by December 31, 2028; 4.8M shares repurchased for $332.7M at $69.30 average in Q2.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$481.0M

Net Income

Q2 2026

$229.9M

Free Cash Flow

Q2 2026

$236.7M

ROIC

Q2 2026

50.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+37.6% YoY

$1.40BFY 2025

FY22 $660.1MFY23 $829.3MFY24 $1.02BFY25 $1.40B

Net Income

-28.6% YoY

$316.9MFY 2025

FY22 $202.1MFY23 $281.6MFY24 $444.1MFY25 $316.9M

Operating Income

-15.0% YoY

$469.0MFY 2025

FY22 $267.5MFY23 $337.6MFY24 $551.5MFY25 $469.0M

EPS (Diluted)

-25.4% YoY

$2.56FY 2025

FY22 $1.44FY23 $2.10FY24 $3.43FY25 $2.56

Total Assets

+22.4% YoY

$2.53BFY 2025

FY22 $1.84BFY23 $1.73BFY24 $2.06BFY25 $2.53B

Total Debt

+42.3% YoY

$2.14BFY 2025

FY22 $1.52BFY23 $1.50BFY24 $1.51BFY25 $2.14B

Op. Cash Flow

+36.0% YoY

$651.6MFY 2025

FY22 $240.1MFY23 $388.6MFY24 $479.1MFY25 $651.6M

Free Cash Flow

+37.6% YoY

$644.6MFY 2025

FY22 $235.3MFY23 $373.3MFY24 $468.4MFY25 $644.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.40B +37.6%	$1.02B +22.4%	$829.3M +25.6%	$660.1M +48.9%	$443.3M +65.7%	$267.6M
Net Income	$316.9M -28.6%	$444.1M +57.7%	$281.6M +39.3%	$202.1M -49.8%	$402.7M +212.0%	$129.1M
Operating Income	$469.0M -15.0%	$551.5M +63.4%	$337.6M +26.2%	$267.5M -3.0%	$275.9M +91.3%	$144.3M
EPS (Diluted)	$2.56 -25.4%	$3.43 +63.3%	$2.10 +45.8%	$1.44 -47.4%	$2.74 +201.1%	$0.91
Total Assets	$2.53B +22.4%	$2.06B +19.1%	$1.73B -5.9%	$1.84B +66.7%	$1.10B +90.4%	$579.9M
Total Debt	$2.14B +42.3%	$1.51B +0.4%	$1.50B -1.3%	$1.52B +57.3%	$966.1M +143.2%	$397.2M
Operating Cash Flow	$651.6M +36.0%	$479.1M +23.3%	$388.6M +61.8%	$240.1M -19.8%	$299.4M +440.0%	$55.5M
Free Cash Flow	$644.6M +37.6%	$468.4M +25.5%	$373.3M +58.6%	$235.3M -21.0%	$298.0M +462.8%	$53.0M

Get alerted when HALO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HALOZYME THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HALO

BlackRock, Inc.
$1.0B13,271,095 sh
VANGUARD CAPITAL MANAGEMENT LLC
$418.8M5,351,312 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$414.8M5,299,008 sh
STATE STREET CORP
$405.4M5,179,434 sh
Invesco Ltd.
$248.7M3,177,997 sh
MORGAN STANLEY
$221.7M2,832,594 sh
Boston Partners
$216.8M2,773,568 sh
BANK OF AMERICA CORP /DE/
$214.5M2,740,561 sh
GEODE CAPITAL MANAGEMENT, LLC
$197.3M2,519,951 sh
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
$196.5M2,511,050 sh

Fund	Value	Shares
BlackRock, Inc.	$1.0B	13,271,095
VANGUARD CAPITAL MANAGEMENT LLC	$418.8M	5,351,312
VANGUARD PORTFOLIO MANAGEMENT LLC	$414.8M	5,299,008
STATE STREET CORP	$405.4M	5,179,434
Invesco Ltd.	$248.7M	3,177,997
MORGAN STANLEY	$221.7M	2,832,594
Boston Partners	$216.8M	2,773,568
BANK OF AMERICA CORP /DE/	$214.5M	2,740,561
GEODE CAPITAL MANAGEMENT, LLC	$197.3M	2,519,951
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	$196.5M	2,511,050

Companies Similar to HALO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ALNY

ALNYLAM PHARMACEUTICALS, INC.

AI score

Similar quality profile · 21 shared holders

CONGRESS ASSET MANAGEMENT CO /MA ROYAL LONDON ASSET MANAGEMENT LTD STEELHEAD PARTNERS LLC

UTHR

UNITED THERAPEUTICS Corp

AI score

Similar quality profile · 19 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.LSV ASSET MANAGEMENT CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

EXEL

EXELIXIS, INC.

AI score

Similar quality profile · 29 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.LSV ASSET MANAGEMENT Stephens Investment Management Group LLC

HRMY

Harmony Biosciences Holdings, Inc.

AI score

Similar quality profile · 15 shared holders

LSV ASSET MANAGEMENT Bridgewater Associates, LP JACOBS LEVY EQUITY MANAGEMENT, INC

PODD

INSULET CORP

AI score

Similar quality profile · 22 shared holders

Stephens Investment Management Group LLC FRONTIER CAPITAL MANAGEMENT CO LLC CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

ANIP

ANI PHARMACEUTICALS INC

AI score

Similar quality profile · 17 shared holders

Alberta Investment Management Corp KENNEDY CAPITAL MANAGEMENT LLC OBERWEIS ASSET MANAGEMENT INC/

LNTH

Lantheus Holdings, Inc.

AI score

Similar quality profile · 25 shared holders

TENOR CAPITAL MANAGEMENT Co., L.P.Boston Partners M&G Plc

DXCM

DEXCOM INC

AI score

Similar quality profile · 19 shared holders

Stephens Investment Management Group LLC TENOR CAPITAL MANAGEMENT Co., L.P.STEELHEAD PARTNERS LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HALO on your watchlist

Track score changes the day HALOZYME THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HALO a good stock to buy?

13F Pro's AI-powered analysis of HALOZYME THERAPEUTICS, INC. (HALO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HALO are available on the HALO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HALO is classified as a large company.

Which hedge funds own HALO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HALO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HALOZYME THERAPEUTICS, INC.'s investment landscape.